Exon skipping induced by CRISPR-directed gene editing regulates the response to chemotherapy in non-small cell lung carcinoma cells

We have been developing CRISPR-directed gene editing as an augmentative therapy for the treatment of non-small cell lung carcinoma (NSCLC) by genetic disruption of Nuclear Factor Erythroid 2-Related Factor 2 (NRF2). NRF2 promotes tumor cell survival in response to therapeutic intervention and thus i...

Descripción completa

Detalles Bibliográficos
Autores principales: Banas, Kelly, Modarai, Shirin, Rivera-Torres, Natalia, Yoo, Byung-Chun, Bialk, Pawel A., Barrett, Connor, Batish, Mona, Kmiec, Eric B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203268/
https://www.ncbi.nlm.nih.gov/pubmed/35314779
http://dx.doi.org/10.1038/s41434-022-00324-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203268/
https://www.ncbi.nlm.nih.gov/pubmed/35314779
http://dx.doi.org/10.1038/s41434-022-00324-7

Ejemplares similares